Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life.Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over Alarm Clock were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and pr